Download PDF
Fortschr Neurol Psychiatr 2012; 80(11): 654-670
DOI: 10.1055/s-0032-1325480
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Sekundärprophylaxe des ischämischen Hirninfarkts – Teil 1

Secondary Prevention of Ischemic Stroke – Part 1
G. F. Hamann
,
M. Liebetrau
Further Information

Publication History

Publication Date:
08 November 2012 (online)

Also available at
    Permissions and Reprints

Lernziele

Der Leser soll den aktuellen Stand der evidenzbasierten Sekundärprävention des Schlaganfalls kennenlernen.

 

  • Literatur

  • 1 Furie KL, Kasner SE, Adams RJ et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2011; 42: 227-276
    CrossrefPubMedGoogle Scholar
  • 2 Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011; 377: 1681-1692
    CrossrefPubMedGoogle Scholar
  • 3 Glader EL, Sjölander M, Eriksson M et al. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41: 397-401
    CrossrefPubMedGoogle Scholar
  • 4 Bushnell CD, Zimmer LO, Pan W et al. Persistence With Stroke Prevention Medications 3 Months After Hospitalization. Arch Neurol 2010; 67: 1456-1463
    CrossrefPubMedGoogle Scholar
  • 5 Hamann GF, Weimar C, Glahn J et al. Adherence to secondary stroke prevention strategies – results from the German Stroke Data Bank. Cerebrovasc Dis 2003; 15: 282288
    PubMedGoogle Scholar
  • 6 Ovbiagele B, Saver JL, Fredieu A et al. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke 2004; 35: 2879-2883
    CrossrefPubMedGoogle Scholar
  • 7 Palnum KH, Mehnert F, Andersen G et al. Medical prophylaxis following hospitalization for ischemic stroke: age- and sex-related differences and relation to mortality. Cerebrovasc Dis 2010; 30: 556-566
    CrossrefPubMedGoogle Scholar
  • 8 Putaala J, Haapaniemi E, Metso AJ et al. Recurrent ischemic events in young adults after first-ever ischemic stroke. Ann Neurol 2010; 68: 661-671
    CrossrefPubMedGoogle Scholar
  • 9 Johnston SC, Albers GW, Gorelick PB et al. National Stroke Association recommendations for systems of care for transient ischemic attack. Ann Neurol 2011; 69: 872-877
    CrossrefPubMedGoogle Scholar
  • 10 Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665
    CrossrefPubMedGoogle Scholar
  • 11 Esler MD, Krum H et al. Symplicity HTN-2 Investigators Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909
    CrossrefPubMedGoogle Scholar
  • 12 Warden BA, Willman AM, Williams CD. Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nat Rev Neurol 2012; 8: 223-235
    PubMedGoogle Scholar
  • 13 Rothwell PM, Wilson M, Price JF et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-1601
    CrossrefPubMedGoogle Scholar
  • 14 Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
    CrossrefPubMedGoogle Scholar
  • 15 Gattellari M, Goumas C, Aitken R et al. Outcomes for patients with ischaemic stroke and atrial fibrillation: the PRISM study (A Program of Research Informing Stroke Management). Cerebrovasc Dis 2011; 32: 370-382 http://www.ncbi.nlm.nih.gov/pubmed?term=%22Worthington%20JM%22%5BAuthor%5D
    CrossrefPubMedGoogle Scholar
  • 16 Duning L, Kirchhof P, Knecht S. Vorhofflimmern in der Neurologie. Nervenheilkunde 2008; 127: 175-186
    PubMedGoogle Scholar
  • 17 Stahrenberg R, Weber-Krüger M, Seegers J et al. Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke 2010; 41: 2884-2888
    CrossrefPubMedGoogle Scholar
  • 18 Wise J. NICE backs new anticoagulant for stroke prevention. BMJ 2012; 344: e2111
    CrossrefPubMedGoogle Scholar
  • 19 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
    CrossrefPubMedGoogle Scholar
  • 20 Diener HC, Connolly SJ, Ezekowitz MD et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-1163
    CrossrefPubMedGoogle Scholar
  • 21 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
    CrossrefPubMedGoogle Scholar
  • 22 Hankey GJ, Patel MR, Stevens SR et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-322
    CrossrefPubMedGoogle Scholar
  • 23 Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817
    CrossrefPubMedGoogle Scholar
  • 24 Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
    CrossrefPubMedGoogle Scholar
  • 25 Easton JD, Lopes RD, Bahit MC et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511
    CrossrefPubMedGoogle Scholar
  • 26 Stöllberger C, Finsterer J. Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation. J Neurol 2012; 259: 168-169
    CrossrefPubMedGoogle Scholar
  • 27 Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thrmoboembolism in patients with atrial fibrillation and risk for stroke or thromboembolism. Circulation 2012; 125: 159-164
    CrossrefPubMedGoogle Scholar
  • 28 Katsnelson M, Sacco RL, Moscucci M. Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants. Stroke 2012; 43: 1179-1185
    CrossrefPubMedGoogle Scholar
  • 29 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402
    CrossrefPubMedGoogle Scholar
  • 30 Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RELY trial. Circulation 2012; 125: 669-676
    CrossrefPubMedGoogle Scholar
  • 31 Johnson WD, Ganjoo AK, Stone CD et al. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg 2000; 17: 718-722
    CrossrefPubMedGoogle Scholar
  • 32 Reddy VY, Holmes D, Doshi SK et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011; 123: 417-424
    CrossrefPubMedGoogle Scholar